Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | AKT1 | P31749 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.70 |
| ▸ | PRKCG | P05129 | 1/20 | 0.70 |
| ▸ | PRKCB | P05771 | 1/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.70 |
| ▸ | PRKCH | P24723 | 1/20 | 0.70 |
| ▸ | PRKCI | P41743 | 1/20 | 0.70 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.70 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.70 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.70 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.70 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231020 | 1.00 | ALDH1A1 (0.70) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL2237831 | 1.00 | ALDH1A1 (0.70) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL93895 | 1.00 | ALDH1A1 (0.70) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL29365750 | 0.91 | ALDH1A1 (0.73) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL29394546 | 0.91 | ALDH1A1 (0.73) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL29905581 | 0.91 | ALDH1A1 (0.73) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL93475 | 0.91 | ALDH1A1 (0.73) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL94022 | 0.91 | ALDH1A1 (0.73) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL53200 | 0.91 | ALDH1A1 (0.73) | ALDH1A1AKT1LMNAMEN1KMT2A | |
| SCHEMBL4320248 | 0.91 | AKT1 (0.83) | ALDH1A1AKT1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563534-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2013-10-22 | — | — | US | disclosed |
| US-8501715-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2013-08-06 | — | — | US | disclosed |
| EP-1626728-B1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2013-07-10 | — | — | EP | disclosed |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-12-27 | — | — | US | disclosed |
| US-8158611-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-04-17 | — | — | US | disclosed |
| EP-2425841-A1 | Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis | Vascular Biogenics Ltd. (IL) | 2012-03-07 | — | — | EP | disclosed |
| US-20110189212-A1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2011-08-04 | — | — | US | disclosed |
| US-7973023-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2011-07-05 | — | — | US | disclosed |
| US-20110097350-A1 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2011-04-28 | — | — | US | disclosed |
| US-7902176-B2 | Etherified oxidized phospholipids for inducing tolerance to oxidized LDL via mucosal administration; 1-hexadecyl-2-(5'-oxo-pentanyl)-sn-glycero-3-phosphocholine (D-ALLE) | VASCULAR BIOGENICS LTD. (IL) | 2011-03-08 | — | — | US | disclosed |
| US-7186704-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2007-03-06 | — | — | US | disclosed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | disclosed |
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-12-08 | — | — | US | disclosed |
| US-6838452-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-01-04 | — | — | US | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2004-06-03 | — | — | US | disclosed |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. | 2003-12-04 | — | — | US | disclosed |
| EP-1341543-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | Vascular Biogenics Ltd. (IL) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002041827-A9 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD (IL) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002041827-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189212-A1 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | ALOX15B, GPX4, ALOX12 | ALDH1A1 1172/4885AKT1 4343/4885LMNA 2680/4885 |
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | ALDH1A1 2337/4885AKT1 3753/4885LMNA 1687/4885 |
| US-20120329757-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | ALDH1A1 2337/4885AKT1 3753/4885LMNA 1687/4885 |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | ALDH1A1 2337/4885AKT1 3753/4885LMNA 1687/4885 |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | ALDH1A1 2337/4885AKT1 3753/4885LMNA 1687/4885 |
| US-20110097350-A1 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | PHOSPHO1, GPX4, SGMS1 | ALDH1A1 2337/4885AKT1 3753/4885LMNA 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.